Comprehensive Stock Comparison
Compare Virax Biolabs Group Limited (VRAX) vs Nautilus Biotechnology, Inc. (NAUT) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  VRAX | Beta 1.24 vs NAUT's 1.71, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) |  NAUT | +99.4% vs VRAX's -86.0% |
| Efficiency (ROA) | NAUT | -31.3% ROA vs VRAX's -199.1% |
Who Each Stock Is For
Income & stability
VRAXbeta 1.24
Growth exposure
VRAXRev growth -96.0%, EPS growth 42.0%
Long-term compounding (10Y)
NAUT-76.9% 10Y total return vs VRAX's -99.9%
Sleep-well-at-night portfolio
VRAXLower volatility, beta 1.24, Low D/E 6.9%, current ratio 7.27x
Defensive / Recession hedge
VRAXBeta 1.24, current ratio 7.27x
Business Model
What each company does and how it makes money
Virax Biolabs Group is a biotechnology company focused on viral disease prevention, detection, and management through diagnostic test kits and medical technology products. It generates revenue primarily from selling diagnostic tests—including rapid antibody, antigen, and PCR tests under the ViraxClear brand—and medical/PPE products under the ViraxCare brand, distributed through clinics, pharmacies, hospitals, and an online platform. The company's competitive advantage lies in its integrated portfolio spanning diagnostics and protective equipment for viral diseases, serving both healthcare institutions and corporate clients across multiple international markets.
Nautilus Biotechnology is a life sciences company developing a proteomics platform to analyze proteins at unprecedented scale and depth. It aims to generate revenue through sales of its integrated platform — including instruments, consumables, and software — though it remains pre-revenue as it develops its technology. The company's potential moat lies in its proprietary single-molecule protein analysis technology, which could enable comprehensive proteome mapping that existing methods cannot achieve.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
VRAX 2NAUT 1VRAX1/1 metricsVRAX3/5 metricsNAUT6/6 metricsVRAX leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). NAUT leads in 1 (Total Returns). 2 tied.
Financial Metrics (TTM)
VRAX and NAUT operate at a comparable scale, with $162,750 and $0 in trailing revenue.
| Metric | VRAXVirax Biolabs Gro… | NAUTNautilus Biotechn… |
|---|---|---|
| RevenueTrailing 12 months | $162,750 | $0 |
| EBITDAEarnings before interest/tax | -$12M | -$60M |
| Net IncomeAfter-tax profit | -$13M | -$63M |
| Free Cash FlowCash after capex | -$13M | -$54M |
| Gross MarginGross profit ÷ Revenue | -1.5% | — |
| Operating MarginEBIT ÷ Revenue | -77.8% | — |
| Net MarginNet income ÷ Revenue | -78.6% | — |
| FCF MarginFCF ÷ Revenue | -77.3% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -98.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +55.6% | +15.4% |
Valuation Metrics
| Metric | VRAXVirax Biolabs Gro… | NAUTNautilus Biotechn… |
|---|---|---|
| Market CapShares × price | $2M | $305M |
| Enterprise ValueMkt cap + debt − cash | -$2M | $322M |
| Trailing P/EPrice ÷ TTM EPS | -0.11x | -5.13x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 241.66x | — |
| Price / BookPrice ÷ Book value/share | 0.12x | 1.94x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
NAUT delivers a -37.1% return on equity — every $100 of shareholder capital generates $-37 in annual profit, vs $-2 for VRAX. VRAX carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to NAUT's 0.19x.
| Metric | VRAXVirax Biolabs Gro… | NAUTNautilus Biotechn… |
|---|---|---|
| ROE (TTM)Return on equity | -2.3% | -37.1% |
| ROA (TTM)Return on assets | -199.1% | -31.3% |
| ROICReturn on invested capital | -2.7% | — |
| ROCEReturn on capital employed | -111.4% | — |
| Piotroski ScoreFundamental quality 0–9 | 1 | 1 |
| Debt / EquityFinancial leverage | 0.07x | 0.19x |
| Net DebtTotal debt minus cash | -$4M | $18M |
| Cash & Equiv.Liquid assets | $4M | $12M |
| Total DebtShort + long-term debt | $377,004 | $30M |
| Interest CoverageEBIT ÷ Interest expense | -149.04x | — |
Total Returns (with DRIP)
A $10,000 investment in NAUT five years ago would be worth $1,821 today (with dividends reinvested), compared to $11 for VRAX. Over the past 12 months, NAUT leads with a +99.4% total return vs VRAX's -86.0%. The 3-year compound annual growth rate (CAGR) favors NAUT at 3.9% vs VRAX's -68.6% — a key indicator of consistent wealth creation.
| Metric | VRAXVirax Biolabs Gro… | NAUTNautilus Biotechn… |
|---|---|---|
| YTD ReturnYear-to-date | -46.3% | +26.3% |
| 1-Year ReturnPast 12 months | -86.0% | +99.4% |
| 3-Year ReturnCumulative with dividends | -96.9% | +12.2% |
| 5-Year ReturnCumulative with dividends | -99.9% | -81.8% |
| 10-Year ReturnCumulative with dividends | -99.9% | -76.9% |
| CAGR (3Y)Annualised 3-year return | -68.6% | +3.9% |
Risk & Volatility
VRAX is the less volatile stock with a 1.24 beta — it tends to amplify market swings less than NAUT's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NAUT currently trades 78.3% from its 52-week high vs VRAX's 12.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VRAXVirax Biolabs Gro… | NAUTNautilus Biotechn… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 1.71x |
| 52-Week HighHighest price in past year | $1.63 | $3.08 |
| 52-Week LowLowest price in past year | $0.19 | $0.62 |
| % of 52W HighCurrent price vs 52-week peak | +12.6% | +78.3% |
| RSI (14)Momentum oscillator 0–100 | 43.5 | 52.1 |
| Avg Volume (50D)Average daily shares traded | 290K | 161K |
Analyst Outlook
| Metric | VRAXVirax Biolabs Gro… | NAUTNautilus Biotechn… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $2.50 |
| # AnalystsCovering analysts | — | 5 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jul 22 | Mar 26 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | 100 | 0.11 | -99.9% |
| Nautilus Biotechnol… (NAUT) | 100 | 84.37 | -15.6% |
Nautilus Biotechnol… (NAUT) returned -82% over 5 years vs Virax Biolabs Group… (VRAX)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2018 | 2025 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | $99876.00 | $6331.00 | -93.7% |
| Nautilus Biotechnol… (NAUT) | $0.00 | $0.00 | — |
Nautilus Biotechnology, Inc.'s revenue grew from $0M (2018) to $0M (2025) — a 0.0% CAGR.
Chart 3EPS Growth — 10 Years
| Stock | 2018 | 2025 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | -0.7 | -1.95 | -178.6% |
| Nautilus Biotechnol… (NAUT) | 87.18 | -0.47 | -100.5% |
Nautilus Biotechnology, Inc.'s EPS grew from $87.18 (2018) to $-0.47 (2025) — a NaN% CAGR.
Chart 4Free Cash Flow — 5 Years
Virax Biolabs Group Limited generated $-5M FCF in 2025 (-776% vs 2021). Nautilus Biotechnology, Inc. generated $-52M FCF in 2025 (-25% vs 2021).
VRAX vs NAUT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is VRAX or NAUT a better buy right now?
Analysts rate Nautilus Biotechnology, Inc. (NAUT) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VRAX or NAUT?
Over the past 5 years, Nautilus Biotechnology, Inc. (NAUT) delivered a total return of -81.8%, compared to -99.9% for Virax Biolabs Group Limited (VRAX). A $10,000 investment in NAUT five years ago would be worth approximately $2K today (assuming dividends reinvested). Over 10 years, the gap is even starker: NAUT returned -76.9% versus VRAX's -99.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VRAX or NAUT?
By beta (market sensitivity over 5 years), Virax Biolabs Group Limited (VRAX) is the lower-risk stock at 1.24β versus Nautilus Biotechnology, Inc.'s 1.71β — meaning NAUT is approximately 37% more volatile than VRAX relative to the S&P 500. On balance sheet safety, Virax Biolabs Group Limited (VRAX) carries a lower debt/equity ratio of 7% versus 19% for Nautilus Biotechnology, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — VRAX or NAUT?
Nautilus Biotechnology, Inc. (NAUT) is the more profitable company, earning 0.0% net margin versus -957.4% for Virax Biolabs Group Limited — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NAUT leads at 0.0% versus -973.4% for VRAX. At the gross margin level — before operating expenses — NAUT leads at 0.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — VRAX or NAUT?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is VRAX or NAUT better for a retirement portfolio?
For long-horizon retirement investors, Virax Biolabs Group Limited (VRAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.24)). Nautilus Biotechnology, Inc. (NAUT) carries a higher beta of 1.71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VRAX: -99.9%, NAUT: -76.9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between VRAX and NAUT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.